Previous 10 | Next 10 |
Clovis Oncology (CLVS) +45% meets key goal for ovarian cancer therapy in late-stage trial. Longeveron (LGVN) +36% publishes peer reviewed study of phase 1 trial results of Lomecel-B for alzheimer’s disease in alzheimer’s & dementia: the journal of the alzheime...
Results Support Further Exploration of Therapeutic Potential of Lomecel-B to Slow Cognitive Decline, Improve Quality of Life for Alzheimer’s Patients Phase 2 Trial Recently Launched With First Patient Treated MIAMI, March 31, 2022 (GLOBE NEWSWIRE) -- Longeveron In...
Mercurity Fintech Holding (MFH) +65%. Fast Radius (FSRD) +21%. Nikola (NKLA) +18% after investor event. Femasys (FEMY) +13%. BiondVax Pharmaceuticals (BVXV) +13% on research pact to develop nanosized antibody therapies. Incannex Healthcare (IXHL) +12%. D-MARKET Elektronik&...
MIAMI, March 24, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that management presented at the Second...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Moonshot Investor newsletter. To make sure you don’t miss any of Tom’s potential 100x picks, subscribe to his mailing list here . Source: bht2000...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Moonshot Investor newsletter. To make sure you don’t miss any of Tom’s potential 100x picks, subscribe to his mailing list here . VOLT Information ...
MIAMI, March 15, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Executive Offic...
Longeveron Inc. (LGVN) Q4 2021 Results Conference Call March 11, 2022 08:30 AM ET Company Participants Brendan Payne - Stern IR Geoff Green - Chief Executive Officer Dr. Joshua Hare - Co-Founder, Chief Science Officer and Chairman James Clavijo - Chief Financial Officer Presentation Operator ...
Gainers: Clearside Biomedical CLSD +38%. Cellectis (NASDAQ:CLLS) +13%. NeuroPace (NASDAQ:NPCE) +12%. 4D pharma LBPS +11%. LifeStance Health (NASDAQ:LFST) +8%. Losers: Orphazyme ORPH -37%. Aesthetic Medical International (NASDAQ:AIH) -19%. Suns...
The clinical-stage biotechnology company Longeveron (NASDAQ:LGVN) has lost ~10% in the pre-market Friday after the company signaled a potential delay for results from its Aging Frailty trial for the lead candidate, Lomecel-B. The data from the Phase 1/2 trial called “HERA...
News, Short Squeeze, Breakout and More Instantly...
Longeveron (NASDAQ: LGVN) , a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, has closed on its previously announced registered direct offering. The offering, which was priced at-the-market ...
MIAMI, July 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today ann...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 113.3% to $0.3178 on volume of 162,323,665 shares NVIDIA Corporation (NVDA) rose 0.8% to $118.92 on volume of 44,858,282 shares Maxeon Solar Technologies Ltd. (MAXN) rose 8.5% to $0.2648 on volume of 43,008,...